# Sven R. Olson

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/sven-r-olson/

## Facts

| Field | Value |
| --- | --- |
| Citations | 1,905 |
| Field | Venous Thromboembolism Diagnosis and Management |
| h-index | 23 |
| i10-index | 35 |
| Last Known Institution | Oregon Health & Science University |
| OpenAlex ID | https://openalex.org/A5060935560 |
| ORCID iD | 0000-0002-2717-4620 |
| Works | 74 |

## Researcher papers

- [Thrombosis and Bleeding in Extracorporeal Membrane Oxygenation (ECMO) Without Anticoagulation: A Systematic Review](https://scholariq.org/papers/thrombosis-and-bleeding-in-extracorporeal-membrane-oxygenation-ecmo-without/)
- [The many roles of tranexamic acid: An overview of the clinical indications for TXA in medical and surgical patients](https://scholariq.org/papers/the-many-roles-of-tranexamic-acid-an-overview-of-the-clinical-indications-for/)
- [The role of iron repletion in adult iron deficiency anemia and other diseases](https://scholariq.org/papers/the-role-of-iron-repletion-in-adult-iron-deficiency-anemia-and-other-diseases/)
- [The contact activation inhibitor AB023 in heparin-free hemodialysis: results of a randomized phase 2 clinical trial](https://scholariq.org/papers/the-contact-activation-inhibitor-ab023-in-heparin-free-hemodialysis-results-of-a/)
- [Contact Activation Inhibitor and Factor XI Antibody, AB023, Produces Safe, Dose-Dependent Anticoagulation in a Phase 1 First-In-Human Trial](https://scholariq.org/papers/contact-activation-inhibitor-and-factor-xi-antibody-ab023-produces-safe-dose/)
- [Deep brain stimulation for obsessive–compulsive disorder: a systematic review and meta-analysis](https://scholariq.org/papers/deep-brain-stimulation-for-obsessive-compulsive-disorder-a-systematic-review-and/)
- [The Safety and Efficacy of Novel Agents Targeting Factors XI and XII in Early Phase Human Trials](https://scholariq.org/papers/the-safety-and-efficacy-of-novel-agents-targeting-factors-xi-and-xii-in-early/)
- [When to Stop Eculizumab in Complement-Mediated Thrombotic Microangiopathies](https://scholariq.org/papers/when-to-stop-eculizumab-in-complement-mediated-thrombotic-microangiopathies/)
- [The contact pathway and sepsis](https://scholariq.org/papers/the-contact-pathway-and-sepsis/)
- [Anticoagulation strategies in extracorporeal circulatory devices in adult populations](https://scholariq.org/papers/anticoagulation-strategies-in-extracorporeal-circulatory-devices-in-adult/)
- [A multicenter study evaluating the effectiveness and safety of single‐dose low molecular weight iron dextran vs single‐dose ferumoxytol for the treatment of iron deficiency](https://scholariq.org/papers/a-multicenter-study-evaluating-the-effectiveness-and-safety-of-single-dose-low/)

## Researcher topics

- [Venous Thromboembolism Diagnosis and Management](https://scholariq.org/topics/venous-thromboembolism-diagnosis-and-management/)
- [Blood Coagulation and Thrombosis Mechanisms](https://scholariq.org/topics/blood-coagulation-and-thrombosis-mechanisms/)
- [Hemophilia Treatment and Research](https://scholariq.org/topics/hemophilia-treatment-and-research/)
- [Coagulation, Bradykinin, Polyphosphates, and Angioedema](https://scholariq.org/topics/coagulation-bradykinin-polyphosphates-and-angioedema/)
- [Atrial Fibrillation Management and Outcomes](https://scholariq.org/topics/atrial-fibrillation-management-and-outcomes/)

## Researcher university

- [Oregon Health & Science University](https://scholariq.org/institutions/oregon-health-and-science-university/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.